Cato BioVentures (CBV) promotes a shared risk business model where important strategic service providers such as Cato Research are aligned with customers to produce efficient and effective outcomes.
RTP, Durham, Noth Carolina (PRWEB) March 24, 2014
Business expert David Gee, Strategic Business Developer of Cato BioVentures is serving as a selected panelist at Life Science Nation: Redefining Early Stage Investment Conference in Boston, Maryland, United States of America. This is an on-going conference series that establishes a circuit for early stage life science companies to explore and discover a variety of sources of funding they need to move forward with their projects.
David Gee will play an active role in the conference panel titled, “CROs: Going Direct, Investing in Emerging Life Sciences”. David, along with three other panelists, will discuss the emerging trend of major service providers taking equity positions in their clients as a means of aligning the interests of both parties. They will also explore the motives and short term/long term impact of this new trend as well as its future in the life science industry.
“Cato BioVentures (CBV) has been doing shared risk investments with clients for more than 23 years. CBV promotes a shared risk business model where important strategic service providers such as Cato Research are aligned with customers to produce efficient and effective outcomes,” says David.
David Gee has more than 30 years of experience within several international healthcare companies serving in sales, marketing, international distribution, strategic planning, corporate investment fund management and business development roles. He has managed commercial activities at all stages of drug development and has extensive experience in establishing research and development collaborations, in-and out-licensing, and M&A. He has considerable product sales and marketing experience in pharmaceuticals, diagnostics and medical devices which includes management of global distribution networks.
For more information, call 919-361-2286, e-mail info(at)cato(dot)com, or visit Cato BioVentures online at http://www.CatoBioVentures.com.
About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization (CRO). For over 23 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital™ in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry’s research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in the company’s overall success. For more information about Cato BioVentures, call 919-361-2286 or visit http://www.CatoBioVentures.com.
About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 250 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost-effectiveness. For more information about Cato Research, visit http://www.Cato.com.